Suspected cancer: recognition and referral (NG12)Product type:GuidanceProgramme:NICE guidelineLast updated: 1 May 2025Published: 23 June 2015
Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer (TA939)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 13 December 2023
Cemiplimab for treating recurrent or metastatic cervical cancer (terminated appraisal) (TA901)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 20 June 2023
Minimally invasive radical hysterectomy for early stage cervical cancer (IPG686)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 27 January 2021
Adjunctive colposcopy technologies for assessing suspected cervical abnormalities: the DYSIS colposcope with DYSISmap and the ZedScan I (DG32)Product type:GuidanceProgramme:Diagnostics guidancePublished: 25 April 2018
Topotecan for the treatment of recurrent and stage IVB cervical cancer (TA183)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 28 October 2009
High dose rate brachytherapy for carcinoma of the cervix (IPG160)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 22 March 2006
Guidance on the use of liquid-based cytology for cervical screening (TA69)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 October 2003